Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Savara Inc. (NASDAQ:SVRA) has been given a consensus rating of “Moderate Buy” by the eight analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.1429.

SVRA has been the subject of several research analyst reports. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th.

Hedge Funds Weigh In On Savara

Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after acquiring an additional 3,205 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of Savara in the 1st quarter valued at approximately $57,000. Russell Investments Group Ltd. increased its holdings in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after purchasing an additional 9,463 shares during the period. Xponance LLC acquired a new position in shares of Savara in the fourth quarter valued at approximately $66,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Savara during the third quarter worth approximately $44,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $5.59 on Monday. The company’s fifty day moving average price is $5.69 and its 200 day moving average price is $5.48. Savara has a 12 month low of $2.98 and a 12 month high of $7.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The firm has a market capitalization of $1.15 billion, a P/E ratio of -9.64 and a beta of 0.29.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, sell-side analysts predict that Savara will post -0.62 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.